Who Paid My Doc
Mark Moss
Allergy Madison, WI Medical Doctor
NPI 1093781163 CMS profile 231530
600 Highland Ave, Madison, WI 53792
General payments
$16,156
Research payments
$2,847
Ownership & investment interest
$0
Research they led as principal investigator
$937,200
Through program year 2024, Mark Moss of Madison, WI is reported in the CMS Open Payments database as having received $16,156 across 24 general payments and $2,847 in research payments paid to them. Separately, studies naming them as principal investigator received $937,200 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 87th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $99 | 1 | |
| 2022 | General | $125 | 1 | |
| 2021 | Research | $2,131 | 1 | |
| 2020 | General | $2,175 | 2 | |
| 2020 | Research | $601 | 2 | |
| 2019 | General | $13,758 | 20 | |
| 2019 | Research | $115 | 1 |
Beside peers
- Mark Moss
- Allergy median
- Middle half of Allergy
- National median
In program year 2025, general payments to Mark Moss were reported at $0. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.
Show as a table
| Year | Mark Moss | Allergy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13,758 | $506 | $151–$1,337 | $163 |
| 2020 | $2,175 | $409 | $108–$1,162 | $114 |
| 2021 | $0 | $549 | $125–$1,485 | $132 |
| 2022 | $125 | $666 | $161–$1,594 | $149 |
| 2023 | $0 | $780 | $186–$1,916 | $160 |
| 2024 | $99 | $1,031 | $271–$2,196 | $164 |
| 2025 | $0 | $1,143 | $226–$2,504 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
359
Drug cost
$170,727
Branded share of claims
47.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xolair Omalizumab | Brand | 35 | $126,383 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 24 | $16,205 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 20 | $8,892 | |
| Fluticasone Propionate Hfa Fluticasone Propionate | Brand | 11 | $6,520 | |
| Odactra Mite,d.Farinae-D.Pteronyssinus | Brand | 11 | $3,632 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 22 | $3,469 | |
| Ventolin Hfa Albuterol Sulfate | Brand | 26 | $1,676 | |
| Fluticasone Propionate | Generic | 46 | $1,166 | |
| Montelukast Sodium | Generic | 69 | $923 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 20 | $720 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 9 billing codesPaid by Medicare
$4,126
Medicare patients
45
Services billed
112
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 51% | |
| Arthritis | 51% | |
| Depression | 31% | |
| COPD | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
28 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy in Wisconsin
Related records
Allergy in Wisconsin
Practitioners in the same specialty and state, ranked by reported value.
All Allergy
Everyone recorded under this specialty, nationwide.
Doctors in Wisconsin
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.